Last reviewed · How we verify
NCT03635619
The Application of 3T MRI in Esophageal Cancer
trial testing No intervention in Esophageal Cancer TNM Staging in 400 participants. Status unknown.
30 December 2023
Quick facts
| Lead sponsor | Henan Cancer Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 400 |
| Start date | 2 September 2018 |
| Primary completion | 30 December 2023 |
| Estimated completion | 30 December 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- No intervention
Conditions studied
- Esophageal Cancer TNM Staging — all drugs for Esophageal Cancer TNM Staging →
- Magnetic Resonance Imaging — all drugs for Magnetic Resonance Imaging →
- Prognosis — all drugs for Prognosis →
Sponsor
Henan Cancer Hospital
Who can join
Adults 18 to 75, any sex, with Esophageal Cancer TNM Staging or Magnetic Resonance Imaging. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
It is very significant that assessing TN staging in esophageal cancer patients before surgery, furthermore, determining the optimize surgical strategy, predict the the efficacy of radiotherapy for patients who were not chosen to be surgeried, and define the range of lymph node for radiotherapy. It has been reported that the application of MRI in metastasis of lymph node of other cancer, but not in metastasis lymph node with esophageal cancer. Only a few studies focused on T staging using conventional MRI in esophageal cancer, however, relatively new sequences in the chest deserve widely used. To develop a pre-treatment evaluation methods for TN staging in patient with esophageal cancer by utilization of the new imaging methods (T2-TSE-BLADE, T2 maps, StarVIBE). By analysising the relationship between TN staging and imaging features to find the imaging characteristics for TN staging, and to find the indicators of magnetic resonance imaging new technology and reference values for facilitate pre-treatment diagnosis of lymphnode metastasis, optimize surgical strategy, predict the the efficacy of adjunctive therapy, and OS and define the range of lymph node for radiotherapy, as making personal treatment planning for esophageal cancer.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Automated segmentation of esophageal squamous cell carcinoma in contrast-enhanced free-breathing 3D-GRE: a comparative study of UNet, nnUNet, and UMamba for tumor delineation.
Han B, Chu F, Shi L, Hu C, et al · · 2025 · PMID 41219837 · DOI 10.1186/s12880-025-02011-6 -
ECR 2025 Book of Abstracts.
· 2025 · PMID 40676413 · DOI 10.1186/s13244-025-02003-8
Verify or expand the search:
- PubMed search for NCT03635619
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of No intervention
Trials testing the same drug.
- NCT06643052 — Cahnge in Management of Suspected Early Onset Neonetal Sepsis After Assimilation of Early Onset Sepsis Calculator · not yet recruiting
- NCT07540611 — Gonadotropin Therapy in Idiopathic Hypogonadal Non-Obstructive · NA · not yet recruiting
- NCT07291778 — Doppler Evaluation for Congestive Acute Kidney Injury in Critical Illness · NA · not yet recruiting
- NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
- NCT07515365 — Colitis Patterns in Patients With Lower GI Symptoms · not yet recruiting
Other Henan Cancer Hospital trials
Trials by the same sponsor.
- NCT07442890 — A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Ro · NA · not yet recruiting
- NCT07472621 — Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma · not yet recruiting
- NCT07459608 — Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma · Phase 2 · not yet recruiting
- NCT07400575 — Anlotinib in Cross-line Treatment of NSCLC and SCLC · not yet recruiting
- NCT07332221 — Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical Trial · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03635619 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Henan Cancer Hospital
- Last refreshed: 1 April 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03635619.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing